Last close As at 05/08/2026
—
— 0.00 (0.00%)
Market capitalisation
—
Research: TMT
In January, CREALOGIX announced the acquisition of Innofis, a Barcelona-based digital banking business, to expand its core digital banking business into the Middle Eastern markets. No financial information on the transaction was provided at the time and, given the size of the deal, the company was required to produce a prospectus, which has revealed all the relevant information. The value of the deal is c CHF39m, which translates to c 3.6x trailing revenues or 9.3x EBITDA. On our updated forecasts, the deal is 11% earnings enhancing (undiluted basis) in FY19.
Written by
CREALOGIX Group |
Forecasts updated for acquisition document |
Prospectus |
Software & comp services |
17 May 2018 |
Share price performance
Business description
Next events
Analyst
CREALOGIX Group is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||
In January, CREALOGIX announced the acquisition of Innofis, a Barcelona-based digital banking business, to expand its core digital banking business into the Middle Eastern markets. No financial information on the transaction was provided at the time and, given the size of the deal, the company was required to produce a prospectus, which has revealed all the relevant information. The value of the deal is c CHF39m, which translates to c 3.6x trailing revenues or 9.3x EBITDA. On our updated forecasts, the deal is 11% earnings enhancing (undiluted basis) in FY19.
Year |
Revenue (CHFm) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
06/16 |
63.3 |
2.2 |
1.65 |
0.00 |
99.0 |
N/A |
06/17 |
74.9 |
5.0 |
2.67 |
0.50 |
61.1 |
0.3 |
06/18e |
88.1 |
10.0 |
5.72 |
1.00 |
28.5 |
0.6 |
06/19e |
102.4 |
14.7 |
7.62 |
1.50 |
21.4 |
0.9 |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Cost of Innofis
The prospectus reveals that CREALOGIX is issuing 170k shares and paying CHF12m in cash for Innofis, which had CHF1.4m in cash on its balance sheet as at 31 December 2017. There is no deferred consideration. Transaction costs are estimated at CHF0.5m. In the year ended December, Innofis generated revenue of CHF10.8m, up 44%, and an operating profit of CHF4.1m for a margin of 37.7%.
Forecasts: Innofis added
We have increased our revenue forecasts by 7% in FY18 and 14% in each of FY19 and FY20 and our EBITDA forecasts increase by 20%, 35% and 34%, respectively. Given the significantly higher operating margins at Innofis, we forecast operating margins to rise by c 250bp. Our adjusted EPS (undiluted basis) increases by 10%, 12% and 14% in the respective years, tempered by the higher share count. Given the rise in the share price, convertible bonds have been actively converting. Hence we now forecast the group to end FY18 with net cash at CHF19.2m (previously CHF18.4m), which rises to CHF28.0m a year later (CHF23.5m). Assuming that the remaining bonds convert will add CHF10.6m of net cash to the balance sheet.
Valuation: 10% growth with 20% operating margins would imply significant upside
The acquisition creates a range of opportunities for management to accelerate revenue growth and boost margins. A discounted cash flow (DCF) scenario incorporating 10% organic revenue CAGR over 2017-27 fading thereafter to 2%, operating margins tapering up to a level of 20% from FY22, along with a 9% WACC, would suggests a valuation of CHF259, 59% above the current share price. Assuming a 25% margin target, all other things being equal, would lift the valuation to CHF317. These valuations are after the dilution impact from the outstanding convertible bonds.
Updated prospectus information on Innofis transaction
CREALOGIX has acquired Innofis from David Moreno, its CEO, founder and 96.5% shareholder, and the minority shareholders. CREALOGIX is issuing 170k shares and paying CHF12m in cash for Innofis, and there is no deferred consideration. Transaction costs are estimated at CHF0.5m. That puts a valuation on the deal at CHF40.7m based on the CHF166 issue price, or CHF39.3m after deducting the CHF1.4m in cash that Innofis had on its balance sheet as at 31 December 2017. There is a lock-in clause whereby the vendors are unable to sell their shares for at least three years. Please refer to our January update note for our initial analysis on the Innofis transaction.
Exhibit 1: Innofis’s selected financial history
€000s |
FY15 |
FY16 |
FY17 |
Revenues |
5,473 |
6,786 |
9,770 |
Change (%) |
24.0 |
44.0 |
|
Operating profit |
2,470 |
2,819 |
3,684 |
Operating margin (%) |
45.1 |
41.5 |
37.7 |
Source: CREALOGIX Group
CREALOGIX’s capital structure
Following the transaction, CREALOGIX retains a strong financial position, as shown in Exhitibt 2, with a net cash position and no bank debt. Further, CREALOGIX’s convertibles bonds have been actively converting, with CHF10.6m nominal outstanding as at 9 May, down from CHF25m as at launch. Consequently CREALOGIX had 1,377,677 shares outstanding at 9 May, including the 170k issued for Innofis, along with CHF10,612,750 in convertibles corresponding to 101,557 voting rights. There were also 107,000 warrants outstanding, which represent 10,700 voting rights.
Exhibit 2: Balance sheet position
CHF000s |
31/12/17 |
31/12/17 |
31/12/17 |
31/12/17 |
Book values |
Acquisition of Innofis* |
Pro forma |
Assume all outstanding bonds convert |
|
Cash & ST securities |
(30,366) |
11,068 |
(19,298) |
(19,298) |
Short-term borrowings |
0 |
0 |
0 |
0 |
Long-term borrowings |
0 |
0 |
0 |
0 |
Convertible bonds |
14,054 |
0 |
14,054 |
0 |
Net cash |
(16,312) |
11,068 |
(5,244) |
(19,298) |
Assumed ELAXY FS&S deferred payment |
2,387 |
2,387 |
2,387 |
|
Adjusted net debt (cash) |
(13,925) |
(2,857) |
(16,911) |
|
Net assets |
41,464 |
25,416 |
66,880 |
80,934 |
Debt/equity |
(33.6%) |
(4.3%) |
(20.9%) |
Source: CREALOGIX Group. Note: *Cash purchase price less cash acquired, less transaction costs.
Forecasts: Innofis added, otherwise unchanged
The group recorded organic growth of 8% in H1, as we reported last month, but management expects this to accelerate in H2. Consequently, CREALOGIX maintained its mid-term guidance with annual sales growth of more than 20%, EBITDA of more than 15%, product sales of 70%+ of the total and international sales of 70%+. For FY18, CREALOGIX now expects 15% revenue growth, including a six-month contribution from Innofis, and at least a 10% EBITDA margin.
We note that the recent weakness in the Swiss franc against the euro provides a tailwind for revenues.
We have added Innofis and otherwise broadly maintained our forecasts. At the current exchange rate of CHF1.18/€, Innofis generated CHF11.5m of revenue in FY17 (vs reported CHF10.8m). We have conservatively assumed CHF5.8m for six months in FY18, growing at 10%, which translates to CHF12.7m in FY19 and CHF14.0m in FY20. We note that the numbers, particularly in the FY18 period, will be sensitive to new licence sales due to the traditional licence model. We have conservatively assumed operating margins of 32.5% for Innofis, which is below the historical levels, but we note that the margins have been declining.
Exhibit 3: The impact of adding Innofis
CHF000s |
FY18 |
FY19 |
FY20 |
CREALOGIX continuing |
|||
Revenues |
82,345 |
89,707 |
97,090 |
Costs |
(73,766) |
(78,787) |
(84,307) |
Operating profit |
8,579 |
10,920 |
12,783 |
Operating margin (%) |
10.4 |
12.2 |
13.2 |
Innofis |
|||
Revenues |
5,768 |
12,691 |
13,960 |
Costs |
(3,894) |
(8,566) |
(9,423) |
Operating profit |
1,875 |
4,124 |
4,537 |
Operating margin (%) |
32.5 |
32.5 |
32.5 |
Combined |
|||
Revenues |
88,113 |
102,398 |
111,050 |
Costs |
(77,660) |
(87,354) |
(93,730) |
Operating profit |
10,454 |
15,044 |
17,320 |
Operating margin (%) |
11.9 |
14.7 |
15.6 |
Source: Edison Investment Research
In all, we have increased our revenue forecasts by 7% in FY18 to CHF88.1m and 14% in each of FY19 and FY20 to CHF102.4m and CHF111.1m respectively. Our EBITDA forecasts increase by 20%, 35% and 34% to CHF11.8m, CHF16.4m and CHF18.7m, respectively. The acquisition boosts operating margins to rise by 140bp in FY18, 250bp in FY19 and 240bp in FY20. We have maintained our interest forecasts since the group maintains a healthy net cash position, and we also maintain our tax charge assumptions. We have ignored intangible amortisation at this stage. Our adjusted EPS (undiluted basis) increases by 10%, 12% and 14% in the respective years, tempered by the higher share count. Given the rise in the share price, convertible bonds have been actively converting. Hence we now forecast the group to end FY18 with net cash slightly higher at CHF19.2m, which rises to CHF27.8m a year later (previously CHF23.5m). Assuming that the remaining bonds convert will add CHF10.6m of net cash to the balance sheet. Consequently, the group has plenty of headroom to make additional bolt-on acquisitions.
Exhibit 4: Forecast changes
2018e |
2019e |
2020e |
|||||||
CHF000s |
Previous |
New |
Change (%) |
Previous |
New |
Change (%) |
Previous |
New |
Change (%) |
Revenues |
|
|
|
|
|
|
|
|
|
Licensing fees |
17,920 |
17,920 |
0 |
21,382 |
21,382 |
0 |
23,146 |
23,146 |
0 |
Maintenance |
25,200 |
25,200 |
0 |
26,670 |
26,670 |
0 |
28,560 |
28,560 |
0 |
Hosting and SaaS services |
7,560 |
7,560 |
0 |
10,800 |
10,800 |
0 |
14,580 |
14,580 |
0 |
Services |
28,200 |
28,200 |
0 |
27,737 |
27,737 |
0 |
27,998 |
27,998 |
0 |
Goods |
3,465 |
3,465 |
0 |
3,119 |
3,119 |
0 |
2,807 |
2,807 |
0 |
Innofis |
|
5,768 |
N/A |
|
12,691 |
N/A |
|
13,960 |
N/A |
Total group revenues |
82,345 |
88,113 |
7 |
89,707 |
102,398 |
14 |
97,090 |
111,050 |
14 |
Growth (%) |
10.0 |
17.7 |
77 |
8.9 |
16.2 |
81 |
8.2 |
8.4 |
3 |
Gross profit |
67,198 |
72,101 |
7 |
74,814 |
85,601 |
14 |
82,428 |
94,294 |
14 |
Gross margin (%) |
81.6 |
81.8 |
|
83.4 |
83.6 |
|
84.9 |
84.9 |
|
Opex before depn & amortisation |
(57,319) |
(60,273) |
5 |
(62,645) |
(69,157) |
10 |
(68,445) |
(75,624) |
10 |
EBITDA |
9,879 |
11,829 |
20 |
12,170 |
16,444 |
35 |
13,983 |
18,670 |
34 |
EBITDA margin (%) |
12.0 |
13.4 |
|
13.6 |
16.1 |
|
14.4 |
16.8 |
|
Normal depreciation |
(1,300) |
(1,375) |
6 |
(1,250) |
(1,400) |
12 |
(1,200) |
(1,350) |
13 |
Adjusted operating profit |
8,579 |
10,454 |
22 |
10,920 |
15,044 |
38 |
12,783 |
17,320 |
35 |
Operating margin (%) |
10.4 |
11.9 |
|
12.2 |
14.7 |
|
13.2 |
15.6 |
|
Growth (%) |
45.0 |
76.7 |
|
27.3 |
43.9 |
|
17.1 |
15.1 |
|
Associates |
250 |
250 |
0 |
263 |
263 |
0 |
276 |
276 |
0 |
Net interest |
(750) |
(750) |
0 |
(650) |
(650) |
0 |
(100) |
(100) |
0 |
Profit before tax norm |
8,079 |
9,954 |
23 |
10,532 |
14,657 |
39 |
12,959 |
17,495 |
35 |
Amortisation of acquired intangibles |
(1,799) |
(1,799) |
0 |
(1,799) |
(1,799) |
0 |
(1,799) |
(1,799) |
0 |
Share-based payments |
0 |
0 |
|
0 |
0 |
|
0 |
0 |
|
Exceptional items (net of tax) |
0 |
(500) |
|
0 |
0 |
|
0 |
0 |
|
Profit before tax |
6,280 |
7,655 |
22 |
8,733 |
12,858 |
47 |
11,160 |
15,696 |
41 |
Taxation |
(2,192) |
(2,717) |
24 |
(2,876) |
(4,030) |
40 |
(3,551) |
(4,822) |
36 |
Minority interest |
(198) |
(212) |
7 |
(108) |
(123) |
14 |
(58) |
(67) |
14 |
Net income |
3,890 |
4,726 |
21 |
5,750 |
8,704 |
51 |
7,550 |
10,808 |
43 |
Statutory EPS (CHF) |
3.58 |
3.85 |
7 |
5.25 |
6.32 |
20 |
6.30 |
7.57 |
20 |
Adjusted EPS (CHF) |
5.24 |
5.72 |
9 |
6.89 |
7.62 |
11 |
7.80 |
8.83 |
13 |
P/E - Adjusted EPS |
|
28.5 |
|
21.4 |
|
18.5 |
|||
Source: Edison Investment Research
Exhibit 5: Financial summary
CHF'000s |
2015 |
2016 |
2017 |
2018e |
2019e |
2020e |
|
Year end 30 June |
Swiss GAAP |
Swiss GAAP |
Swiss GAAP |
Swiss GAAP |
Swiss GAAP |
Swiss GAAP |
|
PROFIT & LOSS |
|||||||
Revenue |
|
49,307 |
63,317 |
74,858 |
88,113 |
102,398 |
111,050 |
Gross Profit |
37,017 |
51,693 |
59,695 |
72,101 |
85,601 |
94,294 |
|
EBITDA |
|
(10,555) |
3,696 |
7,304 |
11,829 |
16,444 |
18,670 |
Adjusted Operating Profit |
|
(11,815) |
2,264 |
5,916 |
10,454 |
15,044 |
17,320 |
Amortisation of acquired intangibles |
(1,616) |
(2,634) |
(1,799) |
(1,799) |
(1,799) |
(1,799) |
|
Exceptionals |
0 |
0 |
0 |
(500) |
0 |
0 |
|
Operating Profit |
(13,431) |
(370) |
4,117 |
8,155 |
13,245 |
15,521 |
|
Associates |
(837) |
517 |
(21) |
250 |
263 |
276 |
|
Net Interest |
95 |
(630) |
(936) |
(750) |
(650) |
(100) |
|
Profit Before Tax (norm) |
|
(12,557) |
2,151 |
4,959 |
9,954 |
14,657 |
17,495 |
Profit Before Tax (Statutory) |
|
(14,173) |
(483) |
3,160 |
7,655 |
12,858 |
15,696 |
Tax |
3,899 |
(130) |
(1,751) |
(2,717) |
(4,030) |
(4,822) |
|
Profit After Tax (norm) |
(8,658) |
2,021 |
3,208 |
7,237 |
10,626 |
12,674 |
|
Profit After Tax (Statutory) |
(10,274) |
(613) |
1,409 |
4,938 |
8,827 |
10,875 |
|
Minority interest |
0 |
(270) |
(360) |
(212) |
(123) |
(67) |
|
Net income (norm) |
(8,658) |
1,751 |
2,848 |
7,025 |
10,503 |
12,607 |
|
Net income (Statutory) |
(10,274) |
(883) |
1,049 |
4,726 |
8,704 |
10,808 |
|
Average Number of Shares Outstanding (m) |
1.06 |
1.06 |
1.07 |
1.23 |
1.38 |
1.43 |
|
EPS - normalised (CHF) |
|
(8.13) |
1.65 |
2.67 |
5.72 |
7.62 |
8.83 |
EPS - Statutory (CHF) |
|
(9.65) |
(0.83) |
0.98 |
3.85 |
6.32 |
7.57 |
Dividend per share (CHF) |
2.00 |
0.00 |
0.50 |
1.00 |
1.50 |
2.00 |
|
Gross Margin (%) |
75.1 |
81.6 |
79.7 |
81.8 |
83.6 |
84.9 |
|
EBITDA Margin (%) |
(21.4) |
5.8 |
9.8 |
13.4 |
16.1 |
16.8 |
|
Op Margin (before GW and except.) (%) |
(24.0) |
3.6 |
7.9 |
11.9 |
14.7 |
15.6 |
|
BALANCE SHEET |
|||||||
Fixed Assets |
|
20,371 |
28,910 |
26,430 |
56,401 |
54,585 |
52,991 |
Intangible assets and deferred tax |
14,115 |
21,004 |
18,119 |
48,320 |
46,521 |
44,722 |
|
Tangible Assets |
1,869 |
1,595 |
1,385 |
1,155 |
1,138 |
1,343 |
|
Investments & pensions |
4,387 |
6,311 |
6,926 |
6,926 |
6,926 |
6,926 |
|
Current Assets |
|
28,217 |
48,275 |
52,495 |
63,024 |
75,218 |
77,704 |
Stocks |
3,447 |
3,661 |
3,419 |
4,024 |
4,677 |
5,072 |
|
Debtors |
11,633 |
17,119 |
15,301 |
18,010 |
20,930 |
22,699 |
|
Cash |
10,815 |
27,495 |
33,775 |
40,989 |
49,611 |
49,934 |
|
Current Liabilities |
|
(19,183) |
(24,752) |
(24,219) |
(28,052) |
(54,055) |
(34,987) |
Creditors |
(19,183) |
(24,752) |
(24,219) |
(28,052) |
(32,218) |
(34,987) |
|
Short term borrowings |
0 |
0 |
0 |
0 |
(21,837) |
0 |
|
Long Term Liabilities |
|
(2,723) |
(27,331) |
(25,191) |
(22,894) |
(1,057) |
(1,057) |
Long term borrowings |
0 |
(24,141) |
(23,154) |
(21,837) |
0 |
0 |
|
Other long term liabilities |
(2,723) |
(3,190) |
(2,037) |
(1,057) |
(1,057) |
(1,057) |
|
Net Assets |
|
26,682 |
25,102 |
29,515 |
68,480 |
74,691 |
94,651 |
CASH FLOW |
|||||||
Operating Cash Flow |
|
(4,503) |
1,281 |
9,735 |
12,270 |
16,956 |
19,225 |
Net Interest |
91 |
5 |
(616) |
(750) |
(650) |
(100) |
|
Tax |
(269) |
(144) |
(1,273) |
(1,178) |
(2,687) |
(3,957) |
|
Capex |
(1,018) |
(486) |
(862) |
(1,145) |
(1,382) |
(1,555) |
|
Acquisitions/disposals |
(4,158) |
(9,350) |
(346) |
(38,788) |
(2,387) |
0 |
|
Financing |
925 |
1,504 |
(215) |
27,387 |
0 |
0 |
|
Dividends |
(2,126) |
0 |
0 |
(954) |
(1,227) |
(2,067) |
|
Net Cash Flow |
(11,058) |
(7,190) |
6,423 |
(3,159) |
8,622 |
11,547 |
|
Opening net debt/(cash) |
|
(21,724) |
(10,815) |
(3,354) |
(9,770) |
(19,152) |
(27,774) |
Other |
149 |
(271) |
(7) |
12,541 |
() |
10,613 |
|
Closing net debt/(cash) |
|
(10,815) |
(3,354) |
(9,770) |
(19,152) |
(27,774) |
(49,934) |
Source: CREALOGIX Group (historics), Edison Investment Research (forecasts). Note: The FY19 outflow represents the final payment for Elaxy FS&S. We have treated the convertible bond conversions in FY18 and FY20 in the Other category.
|
|
Research: Investment Companies
BioPharma Credit (BPCR) offers investors access to a diverse portfolio of secured debt instruments for life science companies based on BPCR’s pool of investment opportunities. The ongoing specialisation and fragmentation of the drug discovery process is translating into an increased number of market players seeking additional funding backed by sales from approved products and/or royalty streams from out-licensed products. During its IPO in March 2017 and follow-on placings, the trust has so far raised gross proceeds of US$1,080m (of which US$339m is in seed assets) and already deployed US$690m in four large deals. It also has outstanding potential commitments of up to US$350m.